Luke Green

961 total citations
7 papers, 200 citations indexed

About

Luke Green is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Luke Green has authored 7 papers receiving a total of 200 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 2 papers in Oncology and 2 papers in Immunology. Recurrent topics in Luke Green's work include Adenosine and Purinergic Signaling (1 paper), Glycosylation and Glycoproteins Research (1 paper) and Viral gastroenteritis research and epidemiology (1 paper). Luke Green is often cited by papers focused on Adenosine and Purinergic Signaling (1 paper), Glycosylation and Glycoproteins Research (1 paper) and Viral gastroenteritis research and epidemiology (1 paper). Luke Green collaborates with scholars based in Switzerland, Germany and United Kingdom. Luke Green's co-authors include Sabine Grüner, Hans‐Joachim Anders, Julia Lichtnekert, Sufyan G. Sayyed, Patrizio Mattei, Holger Schmid, Mi Heon Ryu, Onkar P. Kulkarni, Guido Hartmann and Steven V. Ley and has published in prestigious journals such as Kidney International, Journal of Medicinal Chemistry and Current Opinion in Microbiology.

In The Last Decade

Luke Green

7 papers receiving 195 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luke Green Switzerland 6 81 56 46 39 33 7 200
Wenbin Hong China 5 173 2.1× 83 1.5× 16 0.3× 19 0.5× 31 0.9× 16 297
Elda Meta Italy 7 79 1.0× 13 0.2× 21 0.5× 58 1.5× 14 0.4× 8 180
Christopher M. Schafer United States 11 193 2.4× 19 0.3× 7 0.2× 22 0.6× 17 0.5× 17 296
Huadong Sun United States 8 104 1.3× 83 1.5× 27 0.6× 9 0.2× 61 1.8× 16 256
Brandon Peiffer United States 6 130 1.6× 41 0.7× 4 0.1× 35 0.9× 51 1.5× 11 258
Mónica Erazo United States 7 57 0.7× 24 0.4× 6 0.1× 15 0.4× 23 0.7× 7 210
Juliane Hermann Germany 5 129 1.6× 66 1.2× 19 0.4× 3 0.1× 56 1.7× 12 266
Richard S. Barnett United States 5 62 0.8× 27 0.5× 7 0.2× 14 0.4× 39 1.2× 7 125
Clive Drakeford Ireland 7 77 1.0× 63 1.1× 8 0.2× 7 0.2× 19 0.6× 14 255
Junting Zhang China 11 277 3.4× 23 0.4× 25 0.5× 5 0.1× 13 0.4× 21 368

Countries citing papers authored by Luke Green

Since Specialization
Citations

This map shows the geographic impact of Luke Green's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke Green with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke Green more than expected).

Fields of papers citing papers by Luke Green

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luke Green. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke Green. The network helps show where Luke Green may publish in the future.

Co-authorship network of co-authors of Luke Green

This figure shows the co-authorship network connecting the top 25 collaborators of Luke Green. A scholar is included among the top collaborators of Luke Green based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luke Green. Luke Green is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Green, Luke, et al.. (2022). To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis. Journal of Medical Economics. 26(1). 139–148. 3 indexed citations
2.
Haegel, Hélène, Alberto Toso, Luke Green, et al.. (2022). JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. Journal for ImmunoTherapy of Cancer. 10(1). e003766–e003766. 19 indexed citations
3.
Pinard, Emmanuel, Luke Green, Michael Reutlinger, et al.. (2017). Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy. Journal of Medicinal Chemistry. 60(10). 4444–4457. 23 indexed citations
4.
Scully, Ingrid L., Kena A. Swanson, Luke Green, Kathrin U. Jansen, & Annaliesa S. Anderson. (2015). Anti-infective vaccination in the 21st century—new horizons for personal and public health. Current Opinion in Microbiology. 27. 96–102. 10 indexed citations
5.
Sayyed, Sufyan G., Mi Heon Ryu, Onkar P. Kulkarni, et al.. (2011). An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney International. 80(1). 68–78. 99 indexed citations
6.
Alker, André, Alfred Binggeli, Andreas D. Christ, et al.. (2010). Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorganic & Medicinal Chemistry Letters. 20(15). 4521–4525. 12 indexed citations
7.
Green, Luke, Berthold Hinzen, Stuart J. Ince, et al.. (1998). One-pot Synthesis of Penta- and Hepta-saccharides from Monomeric Mannose Building Blocks Using the Principles of Orthogonality and Reactivity Tuning. Synlett. 1998(4). 440–442. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026